Please login to the form below

Not currently logged in
Email:
Password:

MS symptom drug approved in US

The US FDA has approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis

The US Food and Drug Administration (FDA) has approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). Ampyra is the first therapy to be approved for this use.

The drug will be manufactured by Irish pharmaceutical company, Elan, and will be distributed in the US by Acorda Therapeutics.

Shane Cooke, executive vice president and head of Elan Drug Technologies said: "We wish to congratulate Acorda Therapeutics on the approval of Ampyra, which will bring a very important and much needed therapy to the market for MS sufferers."

Data from clinical trials shows that patients treated with Ampyra had faster walking speeds than those receiving a placebo. MS is a chronic disease affecting the central nervous system, often with disability affects. It is estimated to affect around 400,000 people in the US and 2.5 million people worldwide.

When given in doses higher than the recommended 10mg twice daily, Ampyra can cause seizures. Other reported side effects include insomnia, nausea, weakness and balance disorder.

25th January 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....